Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support - Top-Institutions - MDSpire

Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support

  • By

  • Dan Qiao

  • Lei Nie

  • Shuang Liu

  • Hai-bin Ding

  • June 17, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Hematology
    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Hematology
    • Oncology

Original Source(s)

Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support

  • by Dan Qiao, Lei Nie, Shuang Liu, Hai-bin Ding

  • June 17, 2026

Related Content

Editorial: AntibodyPlus therapeutics in oncology: innovative mechanisms, therapeutic strategies, and clinical advances

The role of LARP1 in breast cancer progression: from prognosis to immune microenvironment remodeling

Effects of dexmedetomidine nasal spray on perioperative anxiety and quality of postoperative recovery in patients undergoing modified radical mastectomy for breast cancer